Public R&D Policy: The Right Turns of the Wrong Screw? The Case of the German Biotechnology Industry

28 Pages Posted: 6 Nov 2005 Last revised: 25 Nov 2014

See all articles by Andreas Fier

Andreas Fier

Deutsche Telekom AG

Oliver Heneric

Center for European Economic Research (ZEW)

Date Written: October 2005

Abstract

The German biotechnology industry missed the accession of this key technology in the 1980s. Policy makers make different efforts to overcome shortcomings and recent gaps. Public funding schemes have been implemented to establish a flourish biotech industry in Germany. We assume that R&D policy was driven blind by the idea to catch up with world's biotech leaders and analyse if Germany's R&D policy lost its origins. We do examine, if Germany sacrifice economic funding principles, in particular not discriminating different kinds of "risk" in the field of biotechnology. The study combines survey data of German biotech companies and public R&D funding data on the firm level. The results shed light on the factors which determine public R&D funding and firm's probability of being funded.

Keywords: Biotechnology, Public Policy, Innovation, Subsidies

JEL Classification: C21, H32, L21, L65, M13, O38

Suggested Citation

Fier, Andreas H. and Heneric, Oliver, Public R&D Policy: The Right Turns of the Wrong Screw? The Case of the German Biotechnology Industry (October 2005). ZEW - Centre for European Economic Research Discussion Paper No. 05-060, Available at SSRN: https://ssrn.com/abstract=838104 or http://dx.doi.org/10.2139/ssrn.838104

Andreas H. Fier (Contact Author)

Deutsche Telekom AG ( email )

Friedrich Ebert Allee 140
Bonn, 53113
Germany
+49 228 181 99520 (Phone)
+49 621 181 99599 (Fax)

HOME PAGE: http://www.telekom.de

Oliver Heneric

Center for European Economic Research (ZEW) ( email )

P.O. Box 10 34 43
L 7,1 D-68161 Mannheim
Germany

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
95
Abstract Views
1,013
rank
301,860
PlumX Metrics